Abuse Liability of Two Modern Oral Nicotine Pouched Products
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21-60
SponsorRAI Services Company
About this trial
This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \[PD\]) and plasma nicotine uptake (pharmacokinetics \[PK\]) during controlled monitored use and following ad libitum use of the study investigational products (IPs) by generally healthy smokers who are also users of smokeless tobacco.
Eligibility criteria
Qualifiers
Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.
Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of consent.
Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in length as primary source of tobacco and who also use ST (e.g., moist snuff).
Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of an investigator.
Disqualifiers
Allergic to or cannot tolerate mint or wintergreen flavoring agents.
Individuals or their family members that have ongoing litigation with tobacco company(ies).
Have used electronic nicotine delivery system or tobacco heating device within the 30 days prior to screening.
Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of an investigator, makes the study participant unsuitable to participate in this clinical study.
Trial design
Treatments tested in this trial
- Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette
- Modern Oral Pouch Wintergreen-A 9 mg Nicotine
- Modern Oral Pouch Wintergreen-B 9 mg Nicotine
- UB loose or pouched moist snuff
Treatment groups
40 Participants
are divided into 4 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov